Table 3.
Baseline and final characteristics (N = 20)
| Baseline | Final | |
|---|---|---|
| Concomitant organisms | ||
| Aspergillus species | 6 (30) | 4 (20) |
| Penicillium species | 5 (25) | 4 (20) |
| Pseudomonas species | 2 (10) | 2 (10) |
| Fusarium species | 1 (5) | 0 (0) |
| Klebsiella oxytoca | 1 (5) | 0 (0) |
| Paecilomyces species | 1 (5) | 1 (5) |
| Symptoms | ||
| Cough | 20 (100) | 17 (85) |
| Sputum | 18 (90) | 16 (80) |
| Shortness of breath | 13 (65) | 12 (60) |
| Fever | 2 (10) | 3 (15) |
| Night sweats | 7 (35) | 4 (20) |
| Fatigue | 4 (20) | 5 (25) |
| Weight loss | 5 (25) | 4 (20) |
Data are presented as n (%). Organisms isolated from sputum specimens at initiation of inhaled amikacin (baseline) and at the time of stopping inhaled amikacin or data abstraction in those patients continuing drug (final). Symptoms noted to be present at baseline or final visits.